
    
      Phase A (3 arm parallel group): All patients randomized during the BEYOND study (Bayer
      306440) to either IFNB 1b group (250µg or 500µg) will continue their previously assigned
      study medication, applying the same level of blinding as during the BEYOND study, All
      patients randomized during the BEYOND study to Copaxone and all patients with premature
      discontinuation of study medication during the BEYOND study will receive open-label IFNB 1b
      250µg.

      Phase B (single arm): All patients will receive open-label IFNB 1b 500µg)

      Randomization: No randomization in this trial, patient's allocation in this follow-up study
      depends only on prior trial groups. The preceding study was randomized.

      The trial is sponsored by Bayer Schering Pharma AG, Germany, Bayer HealthCare and Bayer
      HealthCare Pharmaceuticals Inc.

      Secondary outcome measure "Assessment of patient-reported outcomes (FAMS and EQ 5D: The
      variables FAMS and EQ-5D were not analyzed due to the termination of the study before start
      of Phase B.
    
  